| Literature DB >> 29293570 |
Abstract
BACKGROUND: Leptin receptor (LEPR) plays a pivotal role in the control of body weight, energy metabolism, and insulin sensitivity. Various genetic association studies were performed to evaluate associations of LEPR genetic variants with type 2 diabetes (T2D) susceptibility.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29293570 PMCID: PMC5749718 DOI: 10.1371/journal.pone.0189366
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1A schematic diagram of LEPR exon-intron gene structure spanning 168-kilobase (kb) displaying genomic locations of LEPR K109R (rs1137100) (exon 4), Q223R (rs1137101) (exon 6), S343S (rs1805134, formerly rs3790419) (exon 9), N567N (rs2228301) (exon 12), K656N (rs1805094, formerly rs8179183) (exon 14), P1019P (rs1805096) (exon 20), and 3’ untranslated region (UTR) Ins/Del polymorphisms (exon 20) based on gene structures shown in Thompson et al. (1997) [81] and Hansel et al. (2009) [82], with applications of SeqVISTA [83, 84] to map the locations of these genetic variants.
Only Q223R, K109R, K656N, P1019P and 3’ UTR Ins/Del (i.e., underlined) polymorphisms were meta-analyzed by Yang et al. (2016) [24]. Only Q223R was meta-analyzed by Liu et al. (2015) [69], and only Q223R, K109R, K656N, and P1019P were meta-analyzed by Su et al. (2016) [70]. Filled boxes indicate protein-coding regions, and open boxes indicate non-protein-coding regions, i.e., UTRs. Abbreviations: Del deletion; Ins, insertion; UTR, untranslated region. Unfilled boxes are non-coding regions. Not drawn to scale.
General characteristics of 13 included studies for LEPR Q223R*.
| Age (Mean±SD) | Gender (M/F) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First author, Year | Ethnicity | Definition of T2D | Source of controls | # Cases | Genotype Freq. in cases (AA/AG/GG) | # Controls | Genotype Freq. in controls (AA/AG/GG) | Case | Control | Case | Control | NOS |
| Ali Etemad, 2013 (Malay) [ | Malay | IDF | PB | 145 | 42/17/86 | 133 | 22/20/91 | |||||
| Ali Etemad, 2013 (Chinese) [ | Chinese | IDF | PB | 49 | 13/0/36 | 71 | 6/5/60 | 61.9±9.8 | 53.3±12.4 | 191/93 | 158/123 | 7 |
| Ali Etemad, 2013 (Indian) [ | Indian | IDF | PB | 90 | 37/7/46 | 77 | 23/15/39 | |||||
| Bo Jiang, 2014 [ | Chinese | WHO | PB | 8 | 4/65/273 | 176 | 3/33/117 | 68.1±6.4 | 67.1±7.1 | 121/246 | 75/101 | 9 |
| Ghorban Mohammadzadeh, 2013 [ | Iranian | ADA | HB | 144 | 5/59/80 | 147 | 5/62/80 | 54.33±8.85 | 52.53±7.31 | 58/86 | 63/84 | 8 |
| Malgorzata Roszkowska-Gancarz, 2014 [ | Polish | NA | NA | 190 | 48/98/44 | 542 | 147/266/129 | 47.2±5.3 | NA | 70/120 | 127/225 | 7 |
| W-L Liao, 2012 [ | Taiwanese | ADA | NA | 999 | 8/194/796 | 45 | 1/8/36 | NA | NA | 489/510 | NA | 7 |
| Kyong Soo Park, 2006 [ | Korean | ADA | HB | 775 | 11/177/578 | 688 | 13/148/523 | 58.9±10.5 | 64.2±4.2 | 361/414 | 308/380 | 8 |
| R-T Gan, 2012 [ | Chinese | NA | PB | 301 | 18/83/200 | 172 | 4/47/121 | 52.67±10.74 | 52.8±7.98 | NA | NA | 8 |
| Lin-Shuang Zhao, 2008a [ | Chinese | WHO | NA | 436 | 85/156/195 | 160 | 91/30/39 | NA | 51.1±2.2 | 272/164 | 91/69 | 8 |
| Devi Murugesan, 2010 [ | Indian | NA | HB | 150 | 30/67/53 | 150 | 73/55/22 | NA | NA | NA | NA | 7 |
| Yangdan Zhang, 2011 [ | Chinese | WHO | HB | 172 | 4/40/128 | 164 | 1/63/100 | 66.52±12.94 | 64.7±14.8 | 90/82 | 87/77 | 8 |
| Hong Sun, 2011 [ | Chinese | WHO | PB | 210 | 2/54/147 | 319 | 10/57/239 | NA | NA | 79/131 | 181/138 | 9 |
*For LEPR Q223R, a total of 13 studies from 11 articles were included. In the study of Etemad et al. (2013) [49] three studies were included, i.e., Study_1, Maylay; Study_2, Chinese; and Study_3, Indian. Abbreviations: ADA, American Diabetes Association; Freq, frequency; HB, hospital-based; IDF, International Diabetes Federation; NOS, Newcastle-Ottawa scale; PB, population-based; SD, standard deviation; T2D, type 2 diabetes; T2D, type 2 diabetes; WHO, World Health Organization; NA, not available. The number of cases (or controls) may not be equal to the sum of the genotype frequencies because of genotyping missing data.
**Genotype frequencies for cases and controls were calculated from respective percentage data shown in Table 2 of Etemad et al. (2013) [49] for Malays, Chinese, and Indians, which were the same as reported by Yang et al. (2016) [24]. Summary statistics for Age and Gender were obtained for the total study sample combining Malay, Chinese, and Indian subgroups together of Etemad et al. (2013) [49].
***Summary statistics for Age in T2D controls were computed manually based on subgroup data of Jiang et al. (2014) [50], respectively.
****The data of Roszkowska-Gancarz et al. (2014) [52] were based on 542 controls (128 centenarians, 414 young controls), and 190 T2D cases only. Genotype frequencies for cases and controls and were calculated from respective percentage data shown in Table II of Roszkowska-Gancarz et al. (2014) [52].
General characteristics of 7 included studies for LEPR K109R*.
| Age (Mean±SD) | Gender (M/F) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First author, Year | Ethnicity | Definition of T2D | Source of controls | # Cases | Genotype Freq. in cases (AA/AG/GG) | # Controls | Genotype Freq. in controls (AA/AG/GG) | Case | Control | Case | Control | NOS |
| Bo Jiang, 2014 [ | Chinese | WHO | PB | 369 | 3/81/184 | 176 | 3/35/72 | 68.1±6.4 | 67.1±7.1 | 121/246 | 75/101 | 9 |
| Malgorzata Roszkowska-Gancarz, 2014 [ | Polish | NA | NA | 190 | 48/98/44 | 542 | 147/266/129 | 47.2±5.3 | NA | 70/120 | 197/345 | 7 |
| W-L Liao, 2012 [ | Taiwanese | ADA | NA | 999 | 23/265/705 | 80 | 1/29/50 | NA | NA | 489/510 | NA | 7 |
| Kyong Soo Park, 2006 [ | Korean | ADA | HB | 775 | 31/238/496 | 688 | 22/200/461 | 58.9±10.5 | 64.2±4.2 | 361/414 | 308/380 | 8 |
| Yanchun Qu, 2007 [ | Chinese | ADA | PB | 317 | 11/93/213 | 282 | 8/71/203 | 49.3±13.7 | 45.2±5.7 | 156/161 | 170/112 | 9 |
| Devi Murugesan, 2010 [ | Indian | NA | HB | 150 | 10/40/100 | 150 | 10/48/91 | NA | NA | NA | NA | 7 |
| Miguel Cruz, 2010 [ | Mexican | ADA | PB | 519 | 223/204/59 | 547 | 204/211/49 | 53.4±7.4 | 43.6±6.6 | NA | NA | 8 |
*For LEPR K109R, a total of 7 studies from 7 articles were included. Abbreviations: ADA, American Diabetes Association; Freq, frequency; HB, hospital-based; IDF, International Diabetes Federation; NOS, Newcastle-Ottawa scale; PB, population-based; SD, standard deviation; T2D, type 2 diabetes; T2D, type 2 diabetes; WHO, World Health Organization; NA, not available.
**Summary statistics for Age in T2D controls were computed manually based on subgroup data of Jiang et al. (2014) [50], respectively.
***The data of Roszkowska-Gancarz et al. (2014) [52] were based on 542 controls (128 centenarians, 414 young controls), and 190 T2D cases only. Genotype frequencies for cases and controls were calculated from respective percentage data shown in Table II of Roszkowska-Gancarz et al. (2014) [52].
Fig 2A PRISMA flow diagram depicting the literature search and study selection process.
Abbreviations: EMBASE, Excerpta Medica Database; T2D, type 2 diabetes.
Meta-analysis results of the association between LEPR Q223R and T2D for 5 genetic models*.
| Genetic model | # Studies | # Cases | # Controls | OR (95% CI) | P-value | I2 | tau-squared | PHeterogeneity | Effects model |
|---|---|---|---|---|---|---|---|---|---|
| G vs. A | 13 | 10342 | 3238 | 1.09 (0.80, 1.48) | 0.5989 | 90.20% | 0.285 | < 0.0001 | Random |
| GG vs. AA | 13 | 4258 | 706 | 1.20 (0.64, 2.26) | 0.5741 | 86.10% | 1.032 | < 0.0001 | Random |
| AG vs. AA | 13 | 1826 | 706 | 1.08 (0.58, 2.02) | 0.8177 | 82.90% | 0.9165 | < 0.0001 | Random |
| GG/AG vs. AA | 13 | 6084 | 706 | 1.13 (0.61, 2.10) | 0.6871 | 88.00% | 0.9783 | < 0.0001 | Random |
| GG vs. AG/AA | 13 | 4258 | 2532 | 1.13 (0.87, 1.45) | 0.365 | 75.40% | 0.1573 | < 0.0001 | Random |
*LEPR Q223R is an A→G mutation (i.e., CAG→CGG) in exon 6, such that A is the wild-type allele, and G is the mutant allele.
Abbreviations: CI, confidence interval; OR, odds ratio.
Fig 3Forest plot for association of LEPR Q223R polymorphism with T2D risk under an allele model in total sample (n = 13 studies, random effects model).
Meta-analysis results of the association between LEPR K109R and T2D for 5 genetic models*.
| Genetic model | # Studies | # Cases | # Controls | OR (95% CI) | P-value | I2 | tau-squared | PHeterogeneity | Effects model |
|---|---|---|---|---|---|---|---|---|---|
| G vs. A | 7 | 6940 | 4018 | 0.93 (0.85, 1.03) | 0.1868 | 0.00% | 0 | 0.4292 | Fixed |
| GG vs. AA | 7 | 2563 | 1102 | 0.97 (0.74, 1.26) | 0.8087 | 0.00% | 0 | 0.8206 | Fixed |
| AG vs. AA | 7 | 1814 | 1102 | 0.81 (0.67, 0.97) | 0.0207 | 0.00% | 0 | 0.7008 | Fixed |
| GG/AG vs. AA | 7 | 4377 | 1102 | 0.83 (0.70, 0.99) | 0.0384 | 0.00% | 0 | 0.7389 | Fixed |
| GG vs. AG/AA | 7 | 2563 | 2916 | 0.99 (0.86, 1.17) | 0.8804 | 8.50% | 0.0041 | 0.3635 | Fixed |
*LEPR K109R is an A→G mutation (i.e., AAG→AGG) in exon 4, such that A is the wild-type allele, and G is the mutant allele.
Abbreviations: CI, confidence interval; OR, odds ratio.
Fig 4Forest plot for association of LEPR K109R polymorphism with T2D risk under an allele model in total sample (n = 7 studies, fixed effects model).
Meta-analysis results of the association between LEPR Q223R and T2D for 5 genetic models in Chinese population*.
| Genetic model | # Studies | # Cases | # Controls | OR (95% CI) | P-value | I2 | tau-squared | PHeterogeneity | Effects model |
|---|---|---|---|---|---|---|---|---|---|
| G vs. A | 7 | 5809 | 1335 | 1.10 (0.65, 1.88) | 0.722 | 91.70% | 0.4645 | < 0.0001 | Random |
| GG vs. AA | 7 | 2487 | 250 | 1.17 (0.35, 3.89) | 0.7927 | 86.00% | 2.067 | < 0.0001 | Random |
| AG vs. AA | 7 | 835 | 250 | 1.09 (0.31, 3.88) | 0.8944 | 82.10% | 2.144 | < 0.0001 | Random |
| GG/AG vs. AA | 7 | 3322 | 250 | 1.15 (0.33, 4.00) | 0.8264 | 87.70% | 2.28 | < 0.0001 | Random |
| GG vs. AG/AA | 7 | 2487 | 1085 | 1.13 (0.75, 1.71) | 0.5476 | 78.80% | 0.2298 | < 0.0001 | Random |
*LEPR Q223R is an A→G mutation (i.e., CAG→CGG) in exon 6, such that A is the wild-type allele, and G is the mutant allele.
Abbreviations: CI, confidence interval; OR, odds ratio.
Meta-analysis results of the association between LEPR Q223R and T2D for 5 genetic models in Non-Chinese population*.
| Genetic model | # Studies | # Cases | # Controls | OR (95% CI) | P-value | I2 | tau-squared | PHeterogeneity | Effects model |
|---|---|---|---|---|---|---|---|---|---|
| G vs. A | 6 | 4533 | 1903 | 1.06 (0.73, 1.54) | 0.7679 | 88.50% | 0.1887 | < 0.0001 | Random |
| GG vs. AA | 6 | 1771 | 456 | 1.20 (0.58, 2.47) | 0.6257 | 85.10% | 0.6731 | < 0.0001 | Random |
| AG vs. AA | 6 | 991 | 456 | 0.98 (0.51, 1.86) | 0.9436 | 78.50% | 0.4766 | 0.0003 | Random |
| GG/AG vs. AA | 6 | 2762 | 456 | 1.10 (0.57, 2.10) | 0.7803 | 84.90% | 0.5272 | < 0.0001 | Random |
| GG vs. AG/AA | 6 | 1771 | 1447 | 1.10 (0.78, 1.55) | 0.5816 | 73.50% | 0.1283 | 0.002 | Random |
*LEPR Q223R is an A→G mutation (i.e., CAG→CGG) in exon 6, such that A is the wild-type allele, and G is the mutant allele.
Abbreviations: CI, confidence interval; OR, odds ratio.
Meta-analysis results of the association between LEPR K109R and T2D for 5 genetic models in Chinese population*.
| Genetic model | # Studies | # Cases | # Controls | OR (95% CI) | P-value | I2 | tau-squared | PHeterogeneity | Effects model |
|---|---|---|---|---|---|---|---|---|---|
| G vs. A | 3 | 3428 | 672 | 1.02 (0.83, 1.26) | 0.8574 | 45.80% | 0.0305 | 0.1579 | Fixed |
| GG vs. AA | 3 | 1427 | 49 | 0.96 (0.45, 2.03) | 0.9115 | 0.00% | 0 | 0.4025 | Fixed |
| AG vs. AA | 3 | 574 | 49 | 1.02 (0.47, 2.20) | 0.959 | 0.00% | 0 | 0.4086 | Fixed |
| GG/AG vs. AA | 3 | 2001 | 49 | 0.97 (0.46, 2.05) | 0.9414 | 0.00% | 0 | 0.4121 | Fixed |
| GG vs. AG/AA | 3 | 1427 | 623 | 1.03 (0.81, 1.31) | 0.8044 | 55.10% | 0.0586 | 0.1078 | Fixed |
*LEPR K109R is an A→G mutation (i.e., AAG→AGG) in exon 4, such that A is the wild-type allele, and G is the mutant allele.
Abbreviations: CI, confidence interval; OR, odds ratio.
Meta-analysis results of the association between LEPR K109R and T2D for 5 genetic models in Non-Chinese population*.
| Genetic model | # Studies | # Cases | # Controls | OR (95% CI) | P-value | I2 | tau-squared | PHeterogeneity | Effects model |
|---|---|---|---|---|---|---|---|---|---|
| G vs. A | 4 | 3512 | 3346 | 0.91 (0.81, 1.02) | 0.1094 | 0.00% | 0 | 0.7049 | Fixed |
| GG vs. AA | 4 | 1136 | 1053 | 0.97 (0.73, 1.29) | 0.8284 | 0.00% | 0 | 0.7808 | Fixed |
| AG vs. AA | 4 | 1240 | 1053 | 0.80 (0.66, 0.96) | 0.0167 | 0.00% | 0 | 0.6474 | Fixed |
| GG/AG vs. AA | 4 | 2376 | 1053 | 0.83 (0.69, 0.99) | 0.0348 | 0.00% | 0 | 0.6608 | Fixed |
| GG vs. AG/AA | 4 | 1136 | 2293 | 0.97 (0.81, 1.16) | 0.7098 | 0.00% | 0 | 0.5877 | Fixed |
*LEPR K109R is an A→G mutation (i.e., AAG→AGG) in exon 4, such that A is the wild-type allele, and G is the mutant allele.
Abbreviations: CI, confidence interval; OR, odds ratio.
Sensitivity analysis results of the association between LEPR Q223R and T2D for allelic model*.
| Study omitted | # Studies | OR (95% CI) | P-value | I2 | PHeterogeneity | Effects model |
|---|---|---|---|---|---|---|
| Etemad, 2013 (Malays) | 12 | 1.15 (0.83, 1.57) | 0.4000 | 89.90% | <0.0001 | Random |
| Etemad, 2013 (Chinese) | 12 | 1.17 (0.86, 1.59) | 0.3307 | 90.10% | <0.0001 | Random |
| Etemad, 2013 (India) | 12 | 1.11 (0.80, 1.55) | 0.5210 | 90.80% | <0.0001 | Random |
| Jiang, 2014 | 12 | 1.08 (0.77, 1.50) | 0.6708 | 91.00% | <0.0001 | Random |
| Mohammadzadeh, 2013 | 12 | 1.09 (0.78, 1.53) | 0.6125 | 91.00% | <0.0001 | Random |
| Roszkowska-Gancarz, 2014 | 12 | 1.09 (0.77, 1.55) | 0.6329 | 90.90% | <0.0001 | Random |
| Liao, 2012 | 12 | 1.09 (0.79, 1.51) | 0.6117 | 91.00% | <0.0001 | Random |
| Park, 2006 | 12 | 1.09 (0.77, 1.56) | 0.6165 | 90.80% | <0.0001 | Random |
| Gan, 2012 | 12 | 1.12 (0.80, 1.56) | 0.5049 | 90.60% | <0.0001 | Random |
| Zhao, 2008a | 12 | 0.99 (0.78, 1.27) | 0.9542 | 81.70% | <0.0001 | Random |
| Murugesan, 2010 | 12 | 1.00 (0.74, 1.36) | 0.9748 | 88.50% | <0.0001 | Random |
| Zhang, 2011 | 12 | 1.06 (0.76, 1.47) | 0.7488 | 90.90% | <0.0001 | Random |
| Sun, 2011 | 12 | 1.11 (0.79, 1.54) | 0.5481 | 90.80% | <0.0001 | Random |
*LEPR Q223R is an A→G mutation (i.e., CAG→CGG) in exon 6, such that A is the wild-type allele, and G is the mutant allele.
Abbreviations: CI, confidence interval; OR, odds ratio.
Sensitivity analysis results of the association between LEPR K109R and T2D for allelic model*.
| Study omitted | # Studies | OR (95% CI) | P-value | I2 | PHeterogeneity | Effects model |
|---|---|---|---|---|---|---|
| Jiang, 2014 | 6 | 0.92 (0.83, 1.02) | 0.1178 | 0.00% | 0.4663 | Fixed |
| Roszkowska-Gancarz, 2014 | 6 | 0.95 (0.85, 1.06) | 0.3794 | 2.00% | 0.4035 | Fixed |
| Liao, 2012 | 6 | 0.92 (0.83, 1.02) | 0.0943 | 0.00% | 0.6427 | Fixed |
| Park, 2006 | 6 | 0.95 (0.85, 1.07) | 0.4229 | 10.80% | 0.3463 | Fixed |
| Qu, 2007 | 6 | 0.95 (0.85, 1.06) | 0.3362 | 3.90% | 0.3919 | Fixed |
| Murugesan, 2010 | 6 | 0.94 (0.85, 1.04) | 0.2531 | 11.90% | 0.3388 | Fixed |
| Cruz, 2010 | 6 | 0.91 (0.81, 1.03) | 0.1326 | 7.80% | 0.3666 | Fixed |
*LEPR K109R is an A→G mutation (i.e., AAG→AGG) in exon 4, such that A is the wild-type allele, and G is the mutant allele.
Abbreviations: CI, confidence interval; OR, odds ratio.
Fig 5Funnel plot for association of LEPR Q223R polymorphism with T2D risk under an allele model in total sample (n = 13 studies).
Fig 6Funnel plot for association of LEPR K109R polymorphism with T2D risk under an allele model in total sample (n = 7 studies).
In silico predicted functional effects of LEPR Q223R and K109R*.
| Gene Symbol | SNP ID (WT/MUT alleles; AA change) | Mutation Assessor FI score (Prediction) | BLOSUM62 score (Prediction) | PROVEAN delta Score (Prediction) | PolyPhen-2 score (Prediction) | PANTHER subPSEC score [Pdeleterious (Prediction)] | SNPs&GO Disease probability [RI] Score (Prediction) | SNPs3D SVM score (Prediction) |
|---|---|---|---|---|---|---|---|---|
| Q223R (A/G; rs1137101) | 1.32 (low impact) | 1.00 (evolutionarily more acceptable) | -1.271 (neutral) | 0.282 (benign) | -1.8785 [0.24573 (neutral)] | 0.110 [ | 3.19 (neutral) | |
| K109R (A/G; rs1137100) | 1.67 (low impact) | 2.00 (evolutionarily more acceptable) | -0.378 (neutral) | 0.077 (benign) | -1.75027 [0.22275 (neutral)] | 0.038 [ | 1.79 (neutral) |
*LEPR Q223R is an A→G mutation (i.e., CAG→CGG) in exon 6, such that A is the wild-type allele, and G is the mutant allele.
*Abbreviations: AA, amino acid; BLOSUM, BLOcks SUbstitution Matrix; FI, functional impact; MUT, mutant; LEPR, leptin receptor; PANTHER, Protein ANalysis THrough Evolutionary Relationships; RI, reliability index; SNP, single nucleotide polymorphism; Polyphen-2; Polymorphism Phenotyping v2; PROVEAN, PROtein Variation Effect ANalyzer; subPSEC, subStitution Position-specific Evolutionary Conservation; SVM, support vector machine; WT, wild-type.
Comparison of methods and results of current study with three previously published meta-analysis studies*.
| Category | Yang et al. (2016) | Liu et al. (2015) | Su et al. (2016) | Current study |
|---|---|---|---|---|
| PubMed, EMBASE | PubMed, EMBASE, Web of Science, and Chinese Biomedical Database (CBM) | PubMed, EMBASE, EBSCO, Web of Knowledge, CNKI, SinoMed, Chinese VIP Database, and Chinese Wanfang Database | PubMed, EMBASE, Cochrane Library, Google Scholar | |
| Allele, Homozygote, Dominant, Recessive (4) | Allele, Homozygote, Dominant, Recessive (4) | Allele, Homozygote, Dominant, Recessive (4) | Allele, Homozygote, Heterozygote, Dominant, Recessive (5) | |
| Weaknesses in data extraction: (i) For | Weaknesses in data extraction: for | Weaknesses in data extraction: the allele codings for both | All data extraction problems of three previously published meta-analysis studies were addressed. | |
| [The results shown were those reported by the study, which included incorrectly extracted data as indicated in above “ | [The results shown were those reported by the study, which included incorrectly extracted data as indicated in above “ | [The results shown were those reported by the study, which included incorrectly extracted data as indicated in above “ | ||
| No | Yes | No | Yes | |
| Yes | No | Yes | Yes | |
| Yes | Yes | No | Yes | |
| No | No | Yes | Yes | |
| Yes | Yes | Yes | Yes |
*The multiplicity-corrected α for Yang et al. (2016) [24], Liu et al. (2015) [69], Su et al. (2016) [70] shall be adjusted according to the number of genetic models studied by each study, i.e., 0.05/4 = 0.0125, because each study has applied 4 different genetic models; the originally reported P-values were shown in bold font if the P-values were below this multiplicity-corrected α. The multiplicity-corrected α for the current study is adjusted according to the number of genetic models studied, i.e., 0.05/5 = 0.01, and if the P-value is below this multiplicity-corrected α, would be shown in bold font.